Holen Sie sich die Stockscreener-App
8.94
2.76%
0.24
Handel nachbörslich:
8.94
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - The Motley Fool
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Could a 65.91% Upside Potential Spark Investor Interest? - DirectorsTalk Interviews
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 - The Manila Times
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - Quiver Quantitative
Relay Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire
Investment Report: Is HEES stock suitable for long term investingPortfolio Risk Report & Low Risk Entry Point Tips - baoquankhu1.vn
Relay earnings in focus as FDA breakthrough fuels optimism By Investing.com - Investing.com Australia
Relay Therapeutics (RLAY) to Release Quarterly Earnings on Wednesday - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Trend Review: Will Relay Therapeutics Inc. benefit from government policyWeekly Investment Recap & AI Powered Market Entry Strategies - mfd.ru
Can Relay Therapeutics Inc. expand its profit marginsPortfolio Update Report & Weekly Watchlist of Top Performers - mfd.ru
Relay Therapeutics, Inc. (RLAY) Stock Analysis: 71% Upside Potential as Analysts Show Strong Buy Confidence - DirectorsTalk Interviews
Can Relay Therapeutics Inc. sustain its profitability2025 Bull vs Bear & Low Risk High Reward Trade Ideas - mfd.ru
Relay Therapeutics stock hits 52-week high at $9.16 By Investing.com - Investing.com Australia
Relay Therapeutics (NASDAQ:RLAY) Sets New 12-Month HighTime to Buy? - MarketBeat
Relay Therapeutics stock hits 52-week high at $9.16 - Investing.com
Assessing Relay Therapeutics (RLAY) Valuation After Recent Share Price Momentum And Price To Book Discount - Sahm
Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib - Yahoo Finance
Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run - The Globe and Mail
$207B Market Shift: The Race for Fast Track Approval in Oncology - Investing News Network
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Relay Thera’s zovegalisib wins ‘Breakthrough’ status from FDA - The Pharma Letter
Relay Therapeutics announces Zovegalisib granted therapy designation by FDA for PIK3CA-mutant - marketscreener.com
Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status By Investing.com - Investing.com South Africa
Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status - Investing.com
Relay Therapeutics Announces Breakthrough Therapy Designation for Zovegalisib - TradingView
Relay Therapeutics Announces Zovegalisib Granted - GlobeNewswire
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer - The Manila Times
Aug Retail: Can Relay Therapeutics Inc sustain its profitabilityProfit Target & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors - Finviz
Relay Therapeutics (NASDAQ:RLAY) Shares Up 7.2%Here's Why - MarketBeat
Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors - Yahoo Finance
What Relay Therapeutics (RLAY)'s Zovegalisib Data and Insider Sales Mean For Shareholders - Sahm
Rate Cut: Is Relay Therapeutics Inc a speculative investmentPortfolio Gains Report & Consistent Profit Alerts - baoquankhu1.vn
Movement Recap: Will Relay Therapeutics Inc benefit from government policyWeekly Profit Recap & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring an 88.66% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Relay Therapeutics (RLAY) Valuation Check After Analyst Upgrades And Zovegalisib Breast Cancer Data - Sahm
Relay Therapeutics president sells $166k in RLAY stock By Investing.com - Investing.com Australia
Moving Averages: Is Trex Company Inc stock a buy or sellTrade Analysis Summary & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Guidance Update: Can Relay Therapeutics Inc reach all time highs this year - baoquankhu1.vn
Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 2,686 Shares - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Insider Sells $11,441.30 in Stock - MarketBeat
Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CFO Sells 1,695 Shares of Stock - MarketBeat
Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 11,684 Shares of Stock - MarketBeat
Thomas Catinazzo Sells 13,820 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock - MarketBeat
Rahmer Peter, chief corporate development officer at Relay Therapeutics, sells $100k in shares - Investing.com Canada
Relay Therapeutics president sells $166k in RLAY stock - Investing.com
2.25%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):